Nitric oxide synthase 3 (NOS3) (eNOS)

Nitric oxide synthase 3 (NOS3), commonly referred to as endothelial nitric oxide synthase (eNOS), is a constitutive enzyme primarily localized in the vascular endothelium that catalyzes the production of nitric oxide (NO) from the amino acid L-arginine [2, 6]. NO is a fundamental signaling molecule that maintains cardiovascular health by inducing vasodilation through the activation of soluble guanylate cyclase in smooth muscle cells, inhibiting platelet aggregation, and suppressing leukocyte adhesion to the vessel wall [1, 5]. Under physiological conditions, eNOS exists as a functional dimer; however, under conditions of oxidative stress or cofactor deficiency (specifically tetrahydrobiopterin), the enzyme can become "uncoupled," leading to the production of superoxide instead of NO, which further exacerbates vascular damage [5, 14]. This dysfunction is a hallmark of various cardiovascular and metabolic diseases, including hypertension, atherosclerosis, and diabetes-related complications [1, 13]. Pharmacological modulation of eNOS activity is achieved through direct activators like nebivolol, agents that upregulate its expression such as statins, or the supplementation of essential cofactors and substrates to restore proper enzyme coupling [7, 14, 16]. Beyond its vascular roles, eNOS is also involved in angiogenesis, metabolic regulation, and neuroprotection, making it a significant therapeutic target for a wide range of ischemic and inflammatory disorders [3, 4, 12].

Other names

Endothelial nitric oxide synthaseConstitutive nitric oxide synthasecNOSNOS type IIIEC-NOS

Drugs targeting eNOS primarily act by upregulating its expression (e.g., statins), stimulating its enzymatic activity through phosphorylation (e.g., nebivolol, amlodipine), or providing essential substrates and cofactors (e.g., L-arginine, tetrahydrobiopterin) to restore the production of nitric oxide and prevent enzyme uncoupling [1, 5, 7, 14].